Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooki, Akira, Morita, Satoshi, Iwamoto, Shigeyoshi, Hara, Hiroki, Tanioka, Hiroaki, Satake, Hironaga, Kataoka, Masato, Kotaka, Masahito, Kagawa, Yoshinori, Nakamura, Masato, Shingai, Tatsushi, Ishikawa, Masashi, Miyake, Yasuhiro, Suto, Takeshi, Hashiguchi, Yojiro, Yabuno, Taichi, Sakamoto, Junichi, Tsuji, Akihito, Ando, Masahiko, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050093/
https://www.ncbi.nlm.nih.gov/pubmed/31962002
http://dx.doi.org/10.1002/cam4.2826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050093/
https://www.ncbi.nlm.nih.gov/pubmed/31962002
http://dx.doi.org/10.1002/cam4.2826

Ejemplares similares